HealthEquity Issues Initial FY2027 Outlook and Reaffirms FY2026 Guidance
HQY sits 24% above its 52-week low of $74.07.
Summary
HealthEquity announced its initial financial outlook for fiscal year 2027, projecting revenues between $1.38 billion and $1.41 billion, alongside reaffirming its fiscal year 2026 guidance.
Key Events · Earnings and Guidance · HQY
-
Initial FY2027 Financial Outlook Provided
HealthEquity expects revenues in the range of $1.38 billion to $1.41 billion for the fiscal year ending January 31, 2027.
-
Adjusted EBITDA Margin and HSA Cash Yield Projections
The company anticipates an Adjusted EBITDA margin of 43.8% to 44.3% and a yield on HSA Cash of approximately 3.75% for FY2027.
-
FY2026 Guidance Reaffirmed
HealthEquity reaffirmed its previously provided guidance for the fiscal year ending January 31, 2026, indicating consistent performance expectations.
-
Presentation at J.P. Morgan Healthcare Conference
Management will discuss these estimates during a presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Analysis · HQY · Trade & Services
HealthEquity has provided its initial financial outlook for fiscal year 2027, setting key expectations for investors regarding revenue, Adjusted EBITDA margin, and HSA cash yield. This forward-looking guidance is crucial for analysts and investors to update their models and assess the company's growth trajectory. The reaffirmation of fiscal year 2026 guidance indicates stability and confidence in current performance. The presentation at the J.P. Morgan Healthcare Conference provides a platform for management to elaborate on these figures and their strategic vision.
At the time of this filing, HQY was trading at $92.06 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $74.07 to $116.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.